Skip to content
Study details
Enrolling now

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Novo Nordisk A/S
NCT IDNCT07253285ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

460

Study length

about 7.7 years

Ages

8–18

Locations

34 sites in CA, FL, GA +16

About this study

This trial is testing how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. It has two parts: a main trial and an extension trial. In the main trial, participants will either get CagriSema (a new trial drug), cagrilintide (a new trial drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main trial will not take part in the extension trial. If participants take part in the extension trial, they will get either CagriSema or cagrilintide in this part of it.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Cagrilintide
  • 2.Take Placebo cagrilintide
  • 3.Take Placebo semaglutide
  • +1 more
PhasePhase 3
DrugSemaglutide
Routeoral
Primary goalRelative change in body mass index (BMI)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Relative change in body mass index (BMI)

Secondary: Absolute change in abdominal fat volumes by MRI - subcutaneous fat and visceral fat, Absolute change in thigh muscle and fat volumes by MRI - thigh fat free muscle and thigh subcutaneous fat, Absolute change in total (neck-to-knee) muscle and fat volumes by Magnetic Resonance Imaging (MRI) - total muscle and total fat, Apparent clearance (CL/F) of semaglutide and cagrilintide at steady state, Change in Alanine Transaminase (ALT), Change in BMI Standard Deviation Score (SDS), Change in BMI percentage of the 95th percentile, Change in HbA1c (millimoles per mole [mmol/mol])

Body systems

Endocrinology